Metronomic Chemotherapy: Principles and Lessons Learned from Applications in the Treatment of Metastatic Prostate Cancer
- 7 October 2009
- book chapter
- other
- Published by Springer Science and Business Media LLC
- Vol. 180, 165-183
- https://doi.org/10.1007/978-3-540-78281-0_10
Abstract
By frequent and protracted administration of conventional cytotoxic drugs without prolonged interruptions, the primary treatment target shifts from the tumor cell population to the tumor vasculature. This “metronomic” way of chemotherapy administration results in antivascular effects, the mechanistic basis of which remains to be fully elucidated. We outline the basic aspects of the metronomic concept, describe the results of clinical applications of such chemotherapy by focusing on studies in metastatic prostate cancer, and discuss certain shortcomings. Based on preclinical findings, we finally point to the possible ways to address these shortcomings in order to bring this novel and promising use of conventional anticancer agents to full fruition.Keywords
This publication has 78 references indexed in Scilit:
- Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy RegimensClinical Cancer Research, 2009
- Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinibMolecular Cancer Therapeutics, 2008
- Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatmentMolecular Cancer Therapeutics, 2007
- Molecular and cellular biomarkers for angiogenesis in clinical oncologyDrug Discovery Today, 2007
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's LymphomaClinical Cancer Research, 2006
- Predicting benefit from anti-angiogenic agents in malignancyNature Reviews Cancer, 2006
- Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effectsAnnals Of Oncology, 2005
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnnals Of Oncology, 2002